慢性丙型肝炎患者接受α-2b干扰素治疗后血清新蝶呤、β2-微球蛋白及γ-干扰素的变化
Changes of serum neopterin, beta 2-microglobulin and interferon-gamma in patients with chronic hepatitis C treated with interferon-alpha 2b.
作者信息
Fuchs D, Norkrans G, Wejstal R, Reibnegger G, Weiss G, Weiland O, Schvarcz R, Fryden A, Wachter H
机构信息
Institute for Medical Chemistry and Biochemistry, University of Innsbruck, Austria.
出版信息
Eur J Med. 1992 Jul-Aug;1(4):196-200.
OBJECTIVES
Treatment with interferon (IFN) reduces viral replication and normalizes aminotransferase levels in a significant percentage of patients with non-A, non-B hepatitis or hepatitis C. Soluble immune activation markers were evaluated in patients with hepatitis.
PATIENTS AND METHODS
Serum concentrations of soluble immune activation markers neopterin and beta 2-microglobulin (B2M) were compared to endogenous IFN-gamma levels in 17 patients with chronic hepatitis C before, during and after 9-months of treatment with IFN-alpha 2b.
RESULTS
Before therapy some patients had increased concentrations of the studied variables. During therapy neopterin and B2M concentrations further increased whereas IFN-gamma decreased. IFN-gamma and neopterin levels were correlated before but not during therapy. The correlations between neopterin and B2M were significant throughout the study.
CONCLUSION
The data indicate that IFN-gamma decreases during treatment and IFN-alpha 2b appears to enhance formation of neopterin and B2M.
目的
干扰素（IFN）治疗可使相当比例的非甲非乙型肝炎或丙型肝炎患者的病毒复制减少，转氨酶水平恢复正常。对肝炎患者的可溶性免疫激活标志物进行了评估。
患者与方法
比较了17例慢性丙型肝炎患者在接受α-2b干扰素治疗9个月之前、期间和之后，可溶性免疫激活标志物新蝶呤和β2-微球蛋白（B2M）的血清浓度与内源性IFN-γ水平。
结果
治疗前，部分患者的研究变量浓度升高。治疗期间，新蝶呤和B2M浓度进一步升高，而IFN-γ降低。治疗前IFN-γ与新蝶呤水平相关，但治疗期间不相关。在整个研究过程中，新蝶呤与B2M之间的相关性显著。
结论
数据表明，治疗期间IFN-γ降低，α-2b干扰素似乎会增强新蝶呤和B2M的形成。
Zotero 插件